Dataset Information


Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.

ABSTRACT: BACKGROUND:IGF-1 is an essential neurotrophin produced peripherally and in the brain. Impairments in the brain IGF-1 concentrations might be responsible for some aspects of major depressive disorder (MDD) pathogenesis, whereas peripheral IGF-1 could have the marker value. We aimed: 1) to compare serum IGF-1 levels in MDD patients and healthy controls (HC); 2) to elucidate possible associations between changes in IGF-1 expression and crucial characteristics of the current depressive episode, MDD course; 3) to evaluate IGF-1 dynamics after 8 weeks` vortioxetine treatment. METHODS:Seventy-eight MDD patients (according to DSM-5) and 47 HC were enrolled. Serum IGF-1, psychopathological (MADRS, CGI) and neuropsychological parameters (PDQ-5, RAVLT, TMT-B, DSST) were analyzed in all subjects at admission and 48 patients after 8 weeks` vortioxetine treatment. AUC-ROCs were calculated to determine if the value of serum IGF-1 could separate MDD patients from HC. Multiple regression models were performed to explore relationships between IGF-1 and depressive episode's symptoms. RESULTS:MDD patients had significantly higher serum IGF-1 levels than HC (228 (183-312) ng/ml vs 153 (129-186) ng/ml, p?

PROVIDER: S-EPMC7206727 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7457028 | BioStudies
| S-EPMC7910099 | BioStudies
| S-EPMC7027855 | BioStudies
| S-EPMC5091829 | BioStudies
| S-EPMC4432084 | BioStudies
| S-EPMC8710584 | BioStudies
| S-EPMC9058271 | BioStudies
| S-EPMC4162519 | BioStudies
| S-EPMC6365446 | BioStudies
| S-EPMC6531944 | BioStudies